Hallmarks of Response to Immune Checkpoint Blockade

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 May 20

PMID 28524159

Citations 117

Authors

Alexandria P Cogdill

Miles C Andrews

Jennifer A Wargo

Affiliations

Soon will be listed here.

Abstract

Unprecedented advances have been made in the treatment of cancer through the use of immune checkpoint blockade, with approval of several checkpoint blockade regimens spanning multiple cancer types. However, responses to this form of therapy are not universal, and insights are clearly needed to identify optimal biomarkers of response and to combat mechanisms of therapeutic resistance. A working knowledge of the hallmarks of cancer yields insight into responses to immune checkpoint blockade, although the focus of this is rather tumour-centric and additional factors are pertinent, including host immunity and environmental influences. Herein, we describe the foundation for pillars and hallmarks of response to immune checkpoint blockade, with a discussion of their relevance to immune monitoring and mechanisms of resistance. Evolution of this understanding will ultimately help guide treatment strategies to enhance therapeutic responses.

Citing Articles

Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy.

Zhang J, Wang F, Sun Z, Ye J, Chu H J Nanobiotechnology. 2025; 23(1):161.

PMID: 40033359 PMC: 11874808. DOI: 10.1186/s12951-025-03236-x.

Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool.

Nisar M, Yan T, Cai Y, Wan C Probiotics Antimicrob Proteins. 2025; .

PMID: 39954194 DOI: 10.1007/s12602-025-10468-8.

Immune checkpoint inhibitors: Utilizing patient's own immunity to treat oral cancer.

Phulari R, Solanki B J Oral Maxillofac Pathol. 2025; 28(4):641-650.

PMID: 39949682 PMC: 11819625. DOI: 10.4103/jomfp.jomfp_327_22.

Heterogeneity in Cancer.

MacDonald W, Purcell C, Pinho-Schwermann M, Stubbs N, Srinivasan P, El-Deiry W Cancers (Basel). 2025; 17(3).

PMID: 39941808 PMC: 11816170. DOI: 10.3390/cancers17030441.

Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs.

Stinson J, Barbosa M, Sheen A, Momin N, Fink E, Hampel J Clin Cancer Res. 2024; 30(18):4029-4043.

PMID: 38980919 PMC: 11398984. DOI: 10.1158/1078-0432.CCR-24-0861.

References

Heninger E, Krueger T, Lang J . Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol. 2015; 6:29. PMC: 4316783. DOI: 10.3389/fimmu.2015.00029. View

Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V . CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015; 194(7):3475-86. DOI: 10.4049/jimmunol.1402711. View

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

Boni A, Cogdill A, Dang P, Udayakumar D, Jenny Njauw C, Sloss C . Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010; 70(13):5213-9. DOI: 10.1158/0008-5472.CAN-10-0118. View

Tang D, Shen Y, Sun J, Wen S, Wolchok J, Yuan J . Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2014; 1(4):229-34. PMC: 4636341. DOI: 10.1158/2326-6066.CIR-13-0020. View

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View

Jones P, Baylin S . The epigenomics of cancer. Cell. 2007; 128(4):683-92. PMC: 3894624. DOI: 10.1016/j.cell.2007.01.029. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

10.

Wrangle J, Wang W, Koch A, Easwaran H, Mohammad H, Vendetti F . Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013; 4(11):2067-79. PMC: 3875770. DOI: 10.18632/oncotarget.1542. View

11.

Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G . Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18(6):883-91. PMC: 3645291. DOI: 10.1038/nm.2753. View

12.

Peng W, Chen J, Liu C, Malu S, Creasy C, Tetzlaff M . Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2015; 6(2):202-16. PMC: 4744499. DOI: 10.1158/2159-8290.CD-15-0283. View

13.

Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. PMC: 5744258. DOI: 10.1056/NEJMoa1414428. View

14.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

15.

McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351(6280):1463-9. PMC: 4984254. DOI: 10.1126/science.aaf1490. View

16.

Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamura M . Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep. 2011; 25(5):1271-7. DOI: 10.3892/or.2011.1201. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

19.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

20.

Sivan A, Corrales L, Hubert N, Williams J, Aquino-Michaels K, Earley Z . Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015; 350(6264):1084-9. PMC: 4873287. DOI: 10.1126/science.aac4255. View